^
    2years
    Exceptional Response to Pembrolizumab and Trastuzumab in a Heavily Pretreated Patient With HER2-Positive TMB-H and MSI-H Metastatic Breast Cancer. (PubMed, JCO Precis Oncol)
    No abstract available
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    HER-2 positive • TMB-H • MSI-H/dMMR • TMB-H + HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab)